A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
Clinical trial NCT02185053 · COMPLETED
Trial details
- NCT number
- NCT02185053
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-31
- Primary completion
- 2016-07-31
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.